<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">At first broad-spectrum antibiotics, interferons-α nebulization and anti-viral drugs were used to reduce the viral load [
 <xref rid="bib41" ref-type="bibr">41</xref>] but only remdesivir has shown promising viral impact [
 <xref rid="bib42" ref-type="bibr">42</xref>]. Remdesivir alone and in combination with chloroquine or β-interferon significantly blocked the SARS-CoV-2 replication and patients were found to recover clinically [
 <xref rid="bib43" ref-type="bibr">43</xref>]. Several other anti-virals drugs are currently being evaluated against infection. Moderate results were exhibited by Favipiravir, Nitazoxanide, Ribavirin, Baricitinib, Penciclovir, Ritonavir and Arbidol when tested against infection in vitro clinical isolates and in patients [
 <xref rid="bib44" ref-type="bibr">44</xref>]. Many other formulations have also been tested against COVID-19 infections in humans and mice such as combinations of antibiotic or antivral drugs with the traditional Chinese medicines [
 <xref rid="bib45" ref-type="bibr">45</xref>]. The convalescent plasma therapy was also tested by doctors in Shanghai China and in USA as well in which blood plasma was isolated from clinically treated COVID-19 patients and injected it in the infected patients who showed positive results with rapid recovery [
 <xref rid="bib46" ref-type="bibr">46</xref>].
</p>
